Current Treatment of Alopecia Areata

Research output: Contribution to journalComment/debatepeer-review


The number of alopecia areata (AA) clinical trials with Jak inhibitors of cytoplasmic tyrosine kinases, including Jak1, Jak2, Jak3, and tyrosine-protein kinase has increased significantly since the last Research Summit. This fact means that the conversation about current treatments for AA now also needs to include a discussion of traditionally used off-label therapies as well as evolving therapies as with Jak inhibitors.

Original languageEnglish (US)
Pages (from-to)S28-S30
JournalJournal of Investigative Dermatology Symposium Proceedings
Issue number1
StatePublished - Nov 2020

Bibliographical note

Funding Information:
Funding for the Summit and publication of this supplement was provided by the National Alopecia Areata Foundation. This Summit was supported (in part) by the National Institute of Arthritis and Musculoskeletal and Skin Diseases under Award Number R13AR074890. The opinions or views expressed in this professional supplement are those of the authors and do not necessarily reflect the official views, opinions, or recommendations of the National Institutes of Health or the National Alopecia Areata Foundation.

Funding Information:
MKH has received research funds (grants paid to the institution) from Pfizer, Eli Lilly, Aclaris, and the National Alopecia Areata Foundation.

Publisher Copyright:
© 2020 The Author


Dive into the research topics of 'Current Treatment of Alopecia Areata'. Together they form a unique fingerprint.

Cite this